Scientists test new booster for hepatitis b shot
NCT ID NCT05561673
Summary
This early-stage study tested the safety and immune response of a new ingredient (called AS37) added to a Hepatitis B vaccine. The trial involved 122 healthy adults aged 18-45 who had never been vaccinated against Hepatitis B. Researchers gave participants two shots one month apart to see if the new ingredient was safe and helped the body build a strong immune defense.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
Cologne, 51069, Germany
-
GSK Investigational Site
Hamburg, 22143, Germany
-
GSK Investigational Site
Magdeburg, 39120, Germany
-
GSK Investigational Site
Cambridge, CB2 2GG, United Kingdom
Conditions
Explore the condition pages connected to this study.